Home About ATSDR Press Room A-Z Index Glossary Employment Training Contact Us CDC  
ATSDR/DHHS Agency for Toxic Substances and Disease Registry Agency for Toxic Substances and Disease Registry Department of Health and Human Services ATSDR en Español

Search:

Section Contents
 
Learning Objectives
Pathological Effects
Key Points
Progress Check
 
Case Contents
 
Table of Contents
Cover Page
How to Use the Course
Initial Check
Mass Casualty Events
Cholinesterase Inhibitors
Cholinergic Toxidrome
Nicotinic Receptors
Muscarinic Receptors
Nicotinic/Muscarinic Mixture
Signs and Symptoms
Laboratory Tests
Differential Diagnosis
Pediatric Cases
Exposure History
RBC & Serum Tests
Inhibitors & Byproducts
Management Strategies
Secondary Exposure
Supportive Care
First-Line Medications
Medications: Atropine
Medications: Pralidoxime
Medications: Diazepam
Antidote Stocking
Deprecated Treatments
Medico-Legal Issues
Intermediate Syndrome
Delayed Neuropathy
Chronic Neurotoxicity
Other Issues
Posttest
Literature Cited
 
Related Documents
 
MMG: Nerve Agents
ToxFAQs™: Nerve Agents
 
Case Studies (CSEM)
 
CSEM Home
Continuing Education
Online Registration
 
ATSDR Resources
 
Case Studies (CSEM)
Exposure Pathways
GATHER (GIS)
Health Assessments
Health Statements
Interaction Profiles
Interactive Learning
Managing Incidents
Medical Guidelines
Minimal Risk Levels
Priority List
ToxFAQs™
ToxFAQs™ CABS
Toxicological Profiles
Toxicology Curriculum
 
External Resources
 
CDC
eLCOSH
EPA
Healthfinder®
Medline Plus
NCEH
NIEHS
NIOSH
OSHA
 

Agency for Toxic Substances and Disease Registry
Case Studies in Environmental Medicine (CSEM) 

Cholinesterase Inhibitors
Including Insecticides and Chemical Warfare Nerve Agents
Part 3: What types of pathology do cholinesterase inhibitors cause?


Learning Objectives

Upon completion of this section, you should be able to

  • identify the 4 major types of pathology caused by cholinesterase inhibitors

Categories of Pathological Effects

We have discussed the mechanism behind one form of pathology caused by cholinesterase inhibitors, namely, the build up of acetylcholine. For purposes of our discussion in the Case Study, we will refer to this as the cholinergic toxidrome. However, there are 3 other distinct syndromes associated with exposure to these toxins the pathology of which is less well understood. (Erdman 2004) Each of which will be described in this case study.

Category Description

Cholinergic toxidrome

(Discussed in Part 4)

Clinical findings due to excessive buildup of acetylcholine. (Hack and Hoffman 2004)

Intermediate syndrome

(Discussed in Part 5)

Delayed neuromuscular dysfunction occurring 24-96 hours after a significant, and usually severe, case of poisoning that usually resolves spontaneously within 1-2 weeks. (Karalliedde and Senanayake 1989; Clark 2002; Erdman 2004)

Organophosphate-induced delayed neuropathy (OPIDN)

(Discussed in Part 6)

Delayed neuropathy of unknown cause with onset occurring 1-5 weeks after recovery from acute cholinergic toxidrome (Erdman 2004; Jamal 1997; Clegg and van Gemert 1999; Jokanovic, Stukalov et al. 2002). Milder cases can recover fully; severe cases can result in permanent disability (Jokanovic, Stukalov et al. 2002).

Organophosphorus ester-induced chronic neurotoxicity (OPICN)

(Discussed in Part 7)

Chronic neurotoxicity that lasts for weeks to years after acute exposure. (Abou-Donia 2003)


Key Points

  • There are four pathological conditions attributed to cholinesterase inhibitor exposure
    • The cholinergic toxidrome.
    • The intermediate syndrome.
    • Organophosphate-induced delayed neuropathy (OPIDN).
    • Organophosphorus ester-induced chronic neurotoxicity (OPICN).

Progress Check

6. Which condition(s) consist of neuropathy characteristically occurring 1-5 weeks after recovery from the acute cholinergic toxidrome? (Choose ALL correct answers)
A. Cholinergic toxidrome.
B. Intermediate syndrome.
C. Organophosphate-induced delayed neuropathy (OPIDN).
D. Organophosphorus ester-induced chronic neurotoxicity (OPICN).
E. None of the above.

Answer:

To review relevant content, see Categories of Pathological Effects in this section.


7. Which condition(s) result(s) in chronic neurotoxic effects that persist for years? (Choose ALL correct answers)
A. Cholinergic toxidrome.
B. Intermediate syndrome.
C. Organophosphate-induced delayed neuropathy (OPIDN).
D. Organophosphorus ester-induced chronic neurotoxicity (OPICN).
E. None of the above.

Answer:

To review relevant content, see Categories of Pathological Effects in this section.


Previous Section

Next Section

Revised 2007-10-16.